A review of solifenacin in the treatment of urinary incontinence

Therapeutics and Clinical Risk Management

Volumn 4, Issue 1, 2008, Pages 117-128

  Basra, Ramandeep ^a   Kelleher, Con ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Overactive bladder; Solifenacin; Urinary incontinence

Indexed keywords

DARIFENACIN; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; SOLIFENACIN; TOLTERODINE;

ANTICHOLINERGIC EFFECT; BLADDER TRAINING; BLURRED VISION; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROESOPHAGEAL REFLUX; HUMAN; LOW DRUG DOSE; NONHUMAN; OVERACTIVE BLADDER; PATHOGENESIS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SUSTAINED RELEASE FORMULATION; TORSADE DES POINTES; URINARY URGENCY; URINE INCONTINENCE; XEROSTOMIA;

EID: 41549139603     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Abrams P, Kelleher CJ, Kerr LA, et al. 2000. Overactive bladder significantly affects quality of life. Am J Manag Care, 6(11 Suppl):S580-90.
2. Birns J, Malone-Lee JG, and the Oxybutynin CR study group Controlled-release oxybutynin maintains efficacy with a 43% reduction in side effects compared to conventional treatment. Neurourol Urodyn, 16:429-30.
3. Braverman AS, Luthin GR, Ruggieri MR. 1998. M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am J Physiol, 275:R1654-60.
4. Cardozo L, Prescott K, Serdarevic D, et al. 2003. Can medication prolong warning time [poster]. Presented at ICS, Florence Italy.
5. Cardozo L, Lisec M, Millard R, et al. 2004. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol, 172:1919-24.
6. Cardozo L, Dewilde T, Feyereisl J, et al. 2006. Solifenacin significantly reduces both urgency severity and bother: Results from the flexible dose, placebo controlled, multinational Sunrise study. IUGA, Athens, Greece.
7. Cardozo L, Nagy G, Kiss L, et al. 2006. Solifenacin in the treatment of urgency symptoms of overactive bladder in a flexible dose, placebo controlled trial. The sunrise study IUGA, Athens, Greece.
8. Chalifoux P. 1980. Urinary continence/incontinence. Recognizing warning time: a critical step towards continence. Geriatr Nurs, 1:254-5.
9. Chapple, CR. 2000. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology, 55(5A Suppl):33-46.
10. Chapple CR, Arano P, Bosch J, et al. 2004. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int, 93:71-7.
11. Chapple C, Rechberger T, Al-Shukri S, et al. 2004. Randomized, double-blind placebo-and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int, 93:303-10.
12. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. 2005. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol, 48:464-70.
13. Haab F, Cardozo L, Chapple C, et al. 2005. Long term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol, 47:376-84. Epub 2005 Jan 5.
14. Hatanaka T, Ukai M, Ohtake A, et al. 2003. In vitro tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats and monkeys [poster]. ICS, Florence Italy.
15. Hedge SS, Choppin A, Bonhaus D, et al. 1997. Functional role of M2 and M3 receptors in the urinary bladder of rats in vivo and in vitro. Br J Pharmacol, 120:1409-18.
16. Hedge SS, Eglen RM. 1999. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci, 64:419-28.
17. Irwin D, Milsom I, Hunskaar S, et al. 2006. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol, 50:1306-14.
18. Kay G, Crook T, Rekeda L, et al. 2006. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol, 50:317-26. Epub Apr 19.
19. Kelleher C, Cardozo L, Chapple C, et al. 2005. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int, 95:81-5.
20. Kelleher CJ, Cardozo LD, Khullar V, et al. 1997a. A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol, 104:988-93.
21. Kelleher CJ, Cardozo LD, Khullar V, et al. 1997b. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol, 104:1374-9.
22. Milson I, Abrams P, Cardozo L, et al. 2001. How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. BJU Int, 87:760-6.
23. Monahan BP, Ferguson CL, Killeavy ES, et al. 1990. Torsades de pointes occurring in association with terfenadine use. JAMA, 264P:2788-90.
24. Ohtake A, Hanataka T, Ikeda K, et al. 2003. In vivo bladder selective profile of solifenacin succinate (YM905) over salivary gland in mice and rats [poster]. ICS Florence Italy.
25. Onderwater RCA. 1999. Identification of human liver CYP isoforms involved in the metabolism of YM905. Yamanouchi Europe BV, Registration number D199900072-01.00. International study ID 905-ME-020.
26. Ouslander JG. 2004. Management of overactive bladder. N Engl J Med, 350:786-99.
27. Stewart WF, Van Rooyen JB, Cundiff GW, et al. 2003. Prevalence and burden of overactive bladder in the United States. World J Urol, 20:327-36.
28. Toglia M, Andoh M, Hussain I. 2006a. Solifenacin improves urgency symptoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder [poster]. ICS, Christchurch, New Zealand.
29. Toglia M, Andoh M, Hussain I. 2006b. Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder [poster]. IUGA, Athens, Greece.
30. Yamanouchi Pharma America, Inc. Nov 2004. Vesicare prescribing information [online]. Accessed 17 October 2006. URL: http://www.vesicare.com/assets/Vesicare_prescribing_info.pdf.
31. Zinner N, Susset J, Gittelman M, et al. 2006. Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist; an investigation of warning time in patients with OAB. Int J Clin Pract, 60:119-26.